⚙
AI-generated deep summary
by qwen3.7-flash, 2026-09-24
· read from full text
ⓘ
This study investigated estrogen hypersensitivity syndrome in endometriosis by measuring plasma levels of the chaperone protein Hsp90α before and after administering a single oral dose of estradiol valerate. The research compared 30 women with laparoscopically confirmed endometriosis against 30 controls, finding that while baseline levels were similar, Hsp90 concentrations rose significantly more in the endometriosis group six hours post-administration. The authors identified an absolute increase greater than 8.6 ng/ml or a relative rise exceeding 28.7% as specific diagnostic criteria for the syndrome, noting high sensitivity and specificity. This paper is centrally about endometriosis — specifically, it proposes a functional diagnostic test for estrogen hypersensitivity within this condition.
Abstract
Objectives. The aim of the study was to develop a diagnostic method for estrogen hypersensitivity syndrome in proliferative benign diseases of the female reproductive system. Using the example of endometriosis, changes in the activity of the chaperone protein Hsp90α were determined as a diagnostic biomarker. Methods. The study included 60 women aged 30 to 50 years, thirty of whom had a laparoscopically confirmed diagnosis of endometriosis and 30 were included in the control group. After blood sampling to determine the baseline levels of Hsp90α, the patients were prescribed a single oral dose of estradiol valerate 2 mg tablet. The plasma Hsp90α levels were remeasured 6 h later. Results. No significant change (p>0.05) in baseline Hsp90α concentrations was found between the group of patients with endometriosis and the control group. Six hours after estradiol valerate administration, a significant difference (p<0.001) in Hsp90α levels was observed between the group of patients with endometriosis and the control group. The increase in Hsp90α concentration following the test-load was also more pronounced in women with confirmed endometriosis compared to controls (27.29±15.62 ng/ml and 3.16±4.36 ng/ml, respectively) (p<0.001). ROC analysis indicated that the absolute increase in Hsp90α level of more than 8.6 ng/ml in patients with endometriosis has a sensitivity of 0.93 and a specificity of 0.97 (compared to the control group). This change in relative concentration corresponded to an increase of over 28.7%. Conclusion. The increase in Hsp90α plasma level of more than 30% within 6 h after the test-load is a specific criterion for estrogen hypersensitivity syndrome in endometriosis. Further investigation including other nosological forms (myoma, adenomyosis, endometrial hyperplasia) is required.
Full text
2,127 characters
· extracted from
oa-html
· click to expand
Estrogens hypersensitivity syndrome in endometriosis
Abstract
Objectives. The aim of the study was to develop a diagnostic method for estrogen hypersensitivity syndrome in proliferative benign diseases of the female reproductive system. Using the example of endometriosis, changes in the activity of the chaperone protein Hsp90α were determined as a diagnostic biomarker.
Methods. The study included 60 women aged 30 to 50 years, thirty of whom had a laparoscopically confirmed diagnosis of endometriosis and 30 were included in the control group. After blood sampling to determine the baseline levels of Hsp90α, the patients were prescribed a single oral dose of estradiol valerate 2 mg tablet. The plasma Hsp90α levels were remeasured 6 h later.
Results. No significant change (p>0.05) in baseline Hsp90α concentrations was found between the group of patients with endometriosis and the control group. Six hours after estradiol valerate administration, a significant difference (p<0.001) in Hsp90α levels was observed between the group of patients with endometriosis and the control group. The increase in Hsp90α concentration following the test-load was also more pronounced in women with confirmed endometriosis compared to controls (27.29±15.62 ng/ml and 3.16±4.36 ng/ml, respectively) (p<0.001). ROC analysis indicated that the absolute increase in Hsp90α level of more than 8.6 ng/ml in patients with endometriosis has a sensitivity of 0.93 and a specificity of 0.97 (compared to the control group). This change in relative concentration corresponded to an increase of over 28.7%.
Conclusion. The increase in Hsp90α plasma level of more than 30% within 6 h after the test-load is a specific criterion for estrogen hypersensitivity syndrome in endometriosis. Further investigation including other nosological forms (myoma, adenomyosis, endometrial hyperplasia) is required.
© 2026 Nikolai Nikolaevich Rukhliada, Kristina Andreevna Dudova, published by Slovak Academy of Sciences, Institute of Experimental Endocrinology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.